JP2012107057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012107057A5 JP2012107057A5 JP2012040330A JP2012040330A JP2012107057A5 JP 2012107057 A5 JP2012107057 A5 JP 2012107057A5 JP 2012040330 A JP2012040330 A JP 2012040330A JP 2012040330 A JP2012040330 A JP 2012040330A JP 2012107057 A5 JP2012107057 A5 JP 2012107057A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- following formula
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 4
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68168405P | 2005-05-17 | 2005-05-17 | |
| US68172305P | 2005-05-17 | 2005-05-17 | |
| US68177205P | 2005-05-17 | 2005-05-17 | |
| US68172205P | 2005-05-17 | 2005-05-17 | |
| US60/681,684 | 2005-05-17 | ||
| US60/681,723 | 2005-05-17 | ||
| US60/681,722 | 2005-05-17 | ||
| US60/681,772 | 2005-05-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Division JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012107057A JP2012107057A (ja) | 2012-06-07 |
| JP2012107057A5 true JP2012107057A5 (enExample) | 2012-10-25 |
Family
ID=37431594
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Expired - Lifetime JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
| JP2012040330A Pending JP2012107057A (ja) | 2005-05-17 | 2012-02-27 | 眼障害の治療のための組成物および方法 |
| JP2012225028A Expired - Lifetime JP6288907B2 (ja) | 2005-05-17 | 2012-10-10 | 眼障害の治療のための組成物および方法 |
| JP2015137500A Withdrawn JP2015187165A (ja) | 2005-05-17 | 2015-07-09 | 眼障害の治療のための組成物および方法 |
| JP2017099005A Withdrawn JP2017141297A (ja) | 2005-05-17 | 2017-05-18 | 眼障害の治療のための組成物および方法 |
| JP2019022433A Expired - Lifetime JP6816180B2 (ja) | 2005-05-17 | 2019-02-12 | 眼障害の治療のための組成物および方法 |
| JP2020030710A Pending JP2020079312A (ja) | 2005-05-17 | 2020-02-26 | 眼障害の治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512519A Expired - Lifetime JP5794721B2 (ja) | 2005-05-17 | 2006-05-17 | 眼障害の治療のための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225028A Expired - Lifetime JP6288907B2 (ja) | 2005-05-17 | 2012-10-10 | 眼障害の治療のための組成物および方法 |
| JP2015137500A Withdrawn JP2015187165A (ja) | 2005-05-17 | 2015-07-09 | 眼障害の治療のための組成物および方法 |
| JP2017099005A Withdrawn JP2017141297A (ja) | 2005-05-17 | 2017-05-18 | 眼障害の治療のための組成物および方法 |
| JP2019022433A Expired - Lifetime JP6816180B2 (ja) | 2005-05-17 | 2019-02-12 | 眼障害の治療のための組成物および方法 |
| JP2020030710A Pending JP2020079312A (ja) | 2005-05-17 | 2020-02-26 | 眼障害の治療のための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (34) | US8168655B2 (enExample) |
| EP (3) | EP2444079B1 (enExample) |
| JP (7) | JP5794721B2 (enExample) |
| CN (2) | CN101175488B (enExample) |
| AU (1) | AU2006247136C1 (enExample) |
| CA (3) | CA2985444C (enExample) |
| CY (1) | CY1118660T1 (enExample) |
| DK (2) | DK1881823T3 (enExample) |
| ES (2) | ES2530780T3 (enExample) |
| HU (1) | HUE031979T2 (enExample) |
| LT (1) | LT2444079T (enExample) |
| PL (2) | PL1881823T3 (enExample) |
| PT (2) | PT1881823E (enExample) |
| SI (2) | SI1881823T1 (enExample) |
| WO (1) | WO2006125119A1 (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004287875B2 (en) | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| CN101193862B (zh) | 2005-04-13 | 2013-08-21 | 阿斯特克斯治疗有限公司 | 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途 |
| SI1881823T1 (sl) * | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| US7202209B2 (en) * | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| KR100930467B1 (ko) * | 2007-06-07 | 2009-12-08 | 동아제약주식회사 | 점액분비를 촉진시키는 3',4',5-트리메톡시 플라본 유도체화합물, 그의 제조방법 및 약학적 용도 |
| CA2702984C (en) * | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| EP3632444A3 (en) | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| WO2009139817A2 (en) * | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| CN105943534A (zh) * | 2008-04-15 | 2016-09-21 | 萨可德生物科学公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| JP5411927B2 (ja) * | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| HRP20150097T1 (hr) | 2008-05-07 | 2015-03-27 | The Regents Of The University Of California | Terapijska nadopuna i poboljšanje vlaženja površine oka |
| PE20110854A1 (es) | 2008-09-26 | 2011-12-23 | Boehringer Ingelheim Int | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 |
| WO2010135524A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| AP2012006204A0 (en) | 2009-10-21 | 2012-04-30 | Boehringer Ingelheim Int | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists. |
| JP5542214B2 (ja) | 2009-10-27 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしての複素環化合物 |
| IN2012DN05081A (enExample) * | 2009-12-08 | 2015-10-09 | Boehringer Ingelheim Int | |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
| US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
| US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2013110679A1 (en) * | 2012-01-27 | 2013-08-01 | F. Hoffmann-La Roche Ag | Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US8865772B2 (en) | 2012-07-26 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating skin cancer |
| US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
| US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
| US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| WO2014092958A1 (en) * | 2012-12-10 | 2014-06-19 | Molecular Targeting Technologies, Inc. | Compositions and methods of diagnosing ocular diseases |
| EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| EP3244851B1 (en) | 2015-01-12 | 2024-10-16 | Bausch + Lomb Ireland Limited | Micro-droplet delivery device |
| KR102440162B1 (ko) * | 2015-07-08 | 2022-09-02 | 악세로비젼, 인크. | 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 |
| CN106995439B (zh) * | 2016-01-26 | 2019-09-20 | 镇江圣安医药有限公司 | 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途 |
| WO2017152027A1 (en) | 2016-03-04 | 2017-09-08 | Rynerson James M | Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation |
| CA3033507A1 (en) | 2016-08-12 | 2018-02-15 | Silk Technologies, Ltd. | Silk-derived protein for treating inflammation |
| CA3032695C (en) | 2016-08-19 | 2021-11-23 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
| EP3509585B1 (en) * | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| CN109906120A (zh) | 2017-01-20 | 2019-06-18 | 科达莱昂治疗公司 | 压电流体分配器 |
| CN109134533B (zh) | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| WO2019020580A1 (en) | 2017-07-24 | 2019-01-31 | Interquim, S.A. | PROCESS FOR PREPARING AND PURIFYING LIFITEGRAST ANTAGONIST OF LFA-1 |
| BR112020003276A2 (pt) | 2017-08-18 | 2020-09-01 | Akrivista, LLC | métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| WO2019097547A1 (en) | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| WO2019096996A1 (en) | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| WO2019113483A1 (en) | 2017-12-08 | 2019-06-13 | Kedalion Therapeutics, Inc. | Fluid delivery alignment system |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| WO2019200121A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical ocular delivery methods and devices for use in the same |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3817696B8 (en) | 2018-07-03 | 2024-12-11 | Bausch + Lomb Ireland Limited | Topical ocular delivery devices |
| US11166910B2 (en) * | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| WO2020212755A1 (en) | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2020219475A1 (en) * | 2019-04-22 | 2020-10-29 | Allegro Ophthalmics, Llc | Compositions and methods useable for treatment of dry eye |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
| WO2021016548A1 (en) * | 2019-07-25 | 2021-01-28 | North Carolina State University | Polyiodide binding compounds and methods of use thereof |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| US20220411482A1 (en) | 2019-11-15 | 2022-12-29 | Silk Technologies, Ltd. | Stable formulations of silk-derived protein |
| EP4120973B1 (en) | 2020-04-17 | 2026-06-10 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| CA3180199A1 (en) | 2020-04-17 | 2021-10-21 | Yehuda Ivri | Hydrodynamically actuated preservative free dispensing system |
| US11213551B1 (en) | 2021-04-05 | 2022-01-04 | Korb Research, Llc. | Ocular treatment compositions and methods of use thereof |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN115707698A (zh) * | 2021-08-18 | 2023-02-21 | 辽宁何氏医学院 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酰胺类化合物及其制备方法和应用 |
| WO2023201283A2 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Methods of producing plasma or serum and uses thereof |
| EP4589369A4 (en) * | 2022-09-15 | 2026-08-12 | Nof Corp | CONTACT LENS SOLUTION |
| WO2024215778A1 (en) * | 2023-04-10 | 2024-10-17 | Insitu Biologics, Inc. | Sustained release stable emulsion pharmaceutical formulations |
| WO2025223511A1 (zh) * | 2024-04-25 | 2025-10-30 | 上海翊石医药科技有限公司 | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 |
| WO2026052060A1 (zh) * | 2024-09-06 | 2026-03-12 | 上海翊石医药科技有限公司 | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US744A (en) * | 1838-05-17 | Mode of cutting off steam in steam-engines | ||
| US423439A (en) * | 1890-03-18 | Stove-pipe guard and register | ||
| GB138135A (en) * | 1918-08-13 | 1920-02-05 | Hugh William Gabbett Fairfax | Improvements in automatic firearms |
| US1680610A (en) * | 1926-09-16 | 1928-08-14 | Mary Y Harmon | Batik-frame support |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3876444A (en) * | 1970-04-24 | 1975-04-08 | Gen Electric | Method of treating high strength carbon fibers |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| ATE114972T1 (de) | 1987-11-02 | 1994-12-15 | Baylor College Medicine | Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen. |
| DE68907066T2 (de) | 1988-01-29 | 1993-12-16 | Koken Kk | Verbesserte Formulierungen mit kontrollierter Abgabe. |
| DE3802996A1 (de) * | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| ATE123810T1 (de) | 1988-08-23 | 1995-06-15 | Dana Farber Cancer Inst Inc | Alpha-subeinheit des lfa-1-leukocyt-adhäsions- rezeptors. |
| EP0362531B1 (en) | 1988-09-01 | 1999-11-10 | Bayer Corporation | A human rhinovirus receptor protein that inhibits virus infectivity |
| KR900701846A (ko) | 1988-09-28 | 1990-12-04 | 원본미기재 | 세포간 점착분자 및 이의 결합 리간드 |
| US5149780A (en) * | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| EP0462184A4 (en) | 1989-03-09 | 1992-01-08 | Dana Farber Cancer Institute | Method of treating viral infections using lfa-1 |
| AU5553290A (en) | 1989-04-28 | 1990-11-29 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (enExample) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| JPH06500555A (ja) | 1990-08-27 | 1994-01-20 | カイロン コーポレイション | 病気の処置のためのペプチドの薬物 |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| AU2777092A (en) * | 1991-10-04 | 1993-05-03 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| WO1994011400A1 (en) | 1992-11-18 | 1994-05-26 | Helsinki University Licensing Ltd. Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| PL174772B1 (pl) | 1993-01-06 | 1998-09-30 | Kinerton Ltd | Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy |
| US5672659A (en) * | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE59409322D1 (de) * | 1993-12-03 | 2000-06-08 | Hoffmann La Roche | Essigsäurederivate als Arzneimittel |
| US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| EP0762886A4 (en) | 1994-04-19 | 1999-03-31 | Univ Kansas | ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF |
| US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5585359A (en) * | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ATE170179T1 (de) * | 1994-11-02 | 1998-09-15 | Merck Patent Gmbh | Adhäsionsrezeptor-antagonisten |
| US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| JP3133073B2 (ja) * | 1995-05-29 | 2001-02-05 | ファイザー・インコーポレーテッド | 成長ホルモンの放出を促進するジペプチド類 |
| US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| IL126422A (en) | 1996-04-23 | 2004-02-19 | Kinerton Ltd | Biodegradable acidic polylactic polymers and methods for their preparation |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT944619E (pt) * | 1996-11-27 | 2007-01-31 | Bristol Myers Squibb Pharma Co | Novos antagonistas dos receptores da integrina |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| ES2306482T3 (es) | 1997-08-28 | 2008-11-01 | Novartis Ag | Antagonistas de antigeno-1 funcion con funcion de linfocito. |
| CA2325986A1 (en) * | 1998-03-27 | 1999-10-07 | Genentech, Inc. | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
| PT1037627E (pt) * | 1998-07-14 | 2001-11-30 | Alcon Lab Inc | Utilizacao do acido 11-(3-dimetilaminopropilideno)-6,11-dihidrodibenz¬b,e|oxepin-2-acetico e seus sais derivados farmaceuticamente aceitaveis para a producao de um medicamento para o tratamento de doencas inflamatorias oftalmicas nao-alergicas e para a prebencao da neovascularizacao ocular |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| CA2352389C (en) | 1998-11-27 | 2009-01-20 | Kanji Takada | An oral formulation for gastrointestinal drug delivery |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| NZ511219A (en) * | 1999-01-05 | 2003-05-30 | Univ Southern Australia | Novel agents and methods for treatment and diagnosis of ocular disorders |
| WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| MX339071B (es) * | 1999-03-31 | 2016-05-09 | Janssen Pharmaceutica Nv | Almidon pregelatinizado en una formulacion de liberacion controlada. |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| JP4303438B2 (ja) | 1999-08-18 | 2009-07-29 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | ペプチドの持続放出製剤 |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| EP1223981B1 (en) | 1999-10-22 | 2008-01-16 | Biogen Idec MA Inc. | Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| EP1237575B1 (en) * | 1999-12-14 | 2008-08-06 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis |
| WO2001049249A2 (en) | 1999-12-31 | 2001-07-12 | Rutgers, The State University | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| JP4917726B2 (ja) | 1999-12-31 | 2012-04-18 | ルトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー | ポリマー混合物および活性化合物からなる徐放用医薬製剤 |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| DE60110396T2 (de) | 2000-01-14 | 2006-01-19 | Larson, Richard S., Albuquerque | Peptidische inhibitoren der lfa-1/icam-1 interaktion |
| US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| EP1296943A1 (fr) * | 2000-05-05 | 2003-04-02 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| AU2001268718B2 (en) * | 2000-06-29 | 2006-01-05 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) * | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| IL155683A0 (en) | 2000-11-28 | 2003-11-23 | Genentech Inc | Lfa-1 antagonist compounds |
| WO2002050080A1 (en) | 2000-12-19 | 2002-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| WO2002058672A2 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| DE60216830T2 (de) * | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| JP2005511477A (ja) * | 2001-03-19 | 2005-04-28 | プラエシス ファーマシューティカルズ インコーポレーテッド | 持続放出のための医薬調合物 |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| JP4583751B2 (ja) | 2001-06-06 | 2010-11-17 | アベンティス・フアーマ・リミテッド | 炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン |
| IL162293A0 (en) | 2001-12-19 | 2005-11-20 | Alza Corp | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| KR20040091100A (ko) | 2002-03-04 | 2004-10-27 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 운반체 펩타이드를 함유하는 서방형 의약 조성물 |
| WO2004014365A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| JP2006502183A (ja) | 2002-09-20 | 2006-01-19 | アルコン，インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005042710A1 (en) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| AU2004287875B2 (en) * | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| US7541420B2 (en) * | 2006-06-30 | 2009-06-02 | Sabic Innovative Plastics Ip B.V. | Method for making molded polycarbonate articles with improved color |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| CA2702984C (en) | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| EP3632444A3 (en) * | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM |
| US8337942B2 (en) * | 2009-08-28 | 2012-12-25 | Minsek David W | Light induced plating of metals on silicon photovoltaic cells |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
-
2006
- 2006-05-17 SI SI200631898T patent/SI1881823T1/sl unknown
- 2006-05-17 JP JP2008512519A patent/JP5794721B2/ja not_active Expired - Lifetime
- 2006-05-17 DK DK06770607.7T patent/DK1881823T3/en active
- 2006-05-17 LT LTEP11181066.9T patent/LT2444079T/lt unknown
- 2006-05-17 PL PL06770607T patent/PL1881823T3/pl unknown
- 2006-05-17 HU HUE11181066A patent/HUE031979T2/en unknown
- 2006-05-17 EP EP11181066.9A patent/EP2444079B1/en not_active Expired - Lifetime
- 2006-05-17 US US11/436,906 patent/US8168655B2/en active Active
- 2006-05-17 EP EP06770607.7A patent/EP1881823B1/en not_active Expired - Lifetime
- 2006-05-17 CN CN2006800171884A patent/CN101175488B/zh not_active Ceased
- 2006-05-17 PL PL11181066T patent/PL2444079T3/pl unknown
- 2006-05-17 PT PT06770607T patent/PT1881823E/pt unknown
- 2006-05-17 CA CA2985444A patent/CA2985444C/en not_active Expired - Lifetime
- 2006-05-17 ES ES06770607T patent/ES2530780T3/es not_active Expired - Lifetime
- 2006-05-17 AU AU2006247136A patent/AU2006247136C1/en active Active
- 2006-05-17 WO PCT/US2006/019327 patent/WO2006125119A1/en not_active Ceased
- 2006-05-17 CA CA2609053A patent/CA2609053C/en active Active
- 2006-05-17 CN CN2012100314315A patent/CN102617557A/zh active Pending
- 2006-05-17 PT PT111810669T patent/PT2444079T/pt unknown
- 2006-05-17 EP EP16201157.1A patent/EP3195861A1/en not_active Withdrawn
- 2006-05-17 CA CA2960117A patent/CA2960117C/en not_active Expired - Lifetime
- 2006-05-17 DK DK11181066.9T patent/DK2444079T3/en active
- 2006-05-17 ES ES11181066.9T patent/ES2614080T3/es not_active Expired - Lifetime
- 2006-05-17 SI SI200632151A patent/SI2444079T1/sl unknown
-
2009
- 2009-07-23 US US12/508,367 patent/US8084047B2/en not_active Expired - Lifetime
- 2009-07-23 US US12/508,311 patent/US20100092541A1/en not_active Abandoned
-
2011
- 2011-01-21 US US13/011,760 patent/US8771715B2/en not_active Expired - Lifetime
- 2011-01-21 US US13/011,775 patent/US8758776B2/en not_active Expired - Fee Related
-
2012
- 2012-02-16 US US13/398,542 patent/US8592450B2/en not_active Expired - Lifetime
- 2012-02-27 JP JP2012040330A patent/JP2012107057A/ja active Pending
- 2012-10-10 JP JP2012225028A patent/JP6288907B2/ja not_active Expired - Lifetime
-
2013
- 2013-08-08 US US13/962,369 patent/US20140073666A1/en not_active Abandoned
- 2013-08-08 US US13/962,440 patent/US20140099387A1/en not_active Abandoned
- 2013-10-03 US US14/045,131 patent/US9045457B2/en not_active Expired - Lifetime
- 2013-10-03 US US14/045,159 patent/US10188641B2/en not_active Expired - Lifetime
-
2014
- 2014-05-12 US US14/275,241 patent/US9051297B2/en not_active Expired - Lifetime
- 2014-05-12 US US14/275,159 patent/US9045458B2/en not_active Expired - Lifetime
-
2015
- 2015-01-30 US US14/610,182 patent/US20150140079A1/en not_active Abandoned
- 2015-01-30 US US14/609,743 patent/US20150140075A1/en not_active Abandoned
- 2015-01-30 US US14/610,346 patent/US20150175578A1/en not_active Abandoned
- 2015-01-30 US US14/610,464 patent/US20150174119A1/en not_active Abandoned
- 2015-01-30 US US14/610,043 patent/US20150140078A1/en not_active Abandoned
- 2015-01-30 US US14/610,465 patent/US20150175581A1/en not_active Abandoned
- 2015-01-30 US US14/609,998 patent/US20150140077A1/en not_active Abandoned
- 2015-01-30 US US14/610,370 patent/US20150175579A1/en not_active Abandoned
- 2015-01-30 US US14/610,401 patent/US20150140082A1/en not_active Abandoned
- 2015-01-30 US US14/609,795 patent/US20150216857A1/en not_active Abandoned
- 2015-01-30 US US14/609,967 patent/US20150182520A1/en not_active Abandoned
- 2015-01-30 US US14/609,770 patent/US20150140076A1/en not_active Abandoned
- 2015-01-30 US US14/610,338 patent/US20150140081A1/en not_active Abandoned
- 2015-01-30 US US14/610,318 patent/US20150175577A1/en not_active Abandoned
- 2015-01-30 US US14/610,291 patent/US20150140080A1/en not_active Abandoned
- 2015-01-30 US US14/610,251 patent/US20150152090A1/en not_active Abandoned
- 2015-01-30 US US14/610,414 patent/US20150175580A1/en not_active Abandoned
- 2015-07-09 JP JP2015137500A patent/JP2015187165A/ja not_active Withdrawn
-
2016
- 2016-11-21 US US15/357,237 patent/US20170143690A1/en not_active Abandoned
- 2016-11-30 US US15/364,935 patent/US20170143691A1/en not_active Abandoned
- 2016-12-08 US US15/372,863 patent/US20170143692A1/en not_active Abandoned
- 2016-12-09 US US15/373,604 patent/US20170143693A1/en not_active Abandoned
-
2017
- 2017-02-24 CY CY20171100257T patent/CY1118660T1/el unknown
- 2017-05-18 JP JP2017099005A patent/JP2017141297A/ja not_active Withdrawn
-
2019
- 2019-02-12 JP JP2019022433A patent/JP6816180B2/ja not_active Expired - Lifetime
-
2020
- 2020-02-26 JP JP2020030710A patent/JP2020079312A/ja active Pending
-
2022
- 2022-07-27 US US17/815,256 patent/US12558350B2/en active Active